Longitudinal changes in cardiac function after cisplatin-based chemotherapy for testicular cancer

Annals of Oncology

Volumn 22, Issue 10, 2011, Pages 2286-2293

  Altena, R ^a   Hummel, Y M ^a   Nuver, J ^a   Smit, A J ^a   Lefrandt, J D ^a   de Boer, R A ^a   Voors, A A ^a   van den Berg, M P ^a   de Vries, E G E ^a   Boezen, H M ^a   Gietema, J A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Cardiovascular damage; Cisplatin; Echocardiography; Testicular cancer

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLEOMYCIN; CISPLATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETOPOSIDE; GALECTIN 3; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN I;

ADULT; AGE; AORTA VALVE REGURGITATION; AORTA VALVE STENOSIS; ARTICLE; BLOOD SAMPLING; CANCER CHEMOTHERAPY; CANCER SURVIVOR; CARDIAC IMAGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART CONTRACTION; HEART DISEASE; HEART FUNCTION TEST; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; INCIDENCE; LONGITUDINAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; OBESITY; ONSET AGE; ORCHIECTOMY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC DYSFUNCTION; TESTIS CANCER; TRANSIENT ISCHEMIC ATTACK; TREATMENT DURATION;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CISPLATIN; DISEASE PROGRESSION; ECHOCARDIOGRAPHY; ETOPOSIDE; GALECTIN 3; HEART DISEASES; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; TESTICULAR NEOPLASMS; VENTRICULAR DYSFUNCTION, LEFT; YOUNG ADULT;

EID: 80053155188     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdr408     Document Type: Article

References (34)

1. van den Belt-Dusebout AW, de Wit R, Gietema JA et al. Treatment-specific risks of second malignancies and cardiovascular disease in 5-year survivors of testicular cancer. J Clin Oncol 2007; 25: 4370-4378.
2. Huddart RA, Norman A, Shahidi M et al. Cardiovascular disease as a long-term complication of treatment for testicular cancer. J Clin Oncol 2003; 21: 1513-1523.
3. Meinardi MT, Gietema JA, van der Graaf WT et al. Cardiovascular morbidity in long-term survivors of metastatic testicular cancer. J Clin Oncol 2000; 18: 1725-1732.
4. Strumberg D, Brugge S, Korn MW et al. Evaluation of long-term toxicity in patients after cisplatin-based chemotherapy for non-seminomatous testicular cancer. Ann Oncol 2002; 13: 229-236.
5. Feldman DR, Bosl GJ, Sheinfeld J et al. Medical treatment of advanced testicular cancer. JAMA 2008; 299: 672-684.
6. Travis LB, Beard C, Allan JM et al. Testicular cancer survivorship: research strategies and recommendations. J Natl Cancer Inst 2010; 102: 1114-1130.
7. Nuver J, Smit AJ, Sleijfer DT et al. Left ventricular and cardiac autonomic function in survivors of testicular cancer. Eur J Clin Invest 2005; 35: 99-103.
8. Altena R, de Haas EC, Nuver J et al. Evaluation of sub-acute changes in cardiac function after cisplatin-based combination chemotherapy for testicular cancer. Br J Cancer 2009; 100: 1861-1866.
9. Ewer MS, Lenihan DJ. Left ventricular ejection fraction and cardiotoxicity: is our ear really to the ground? J Clin Oncol 2008; 26: 1201-1203.
10. Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 2002; 105: 1387-1393.
11. Schillaci G, Pasqualini L, Verdecchia P et al. Prognostic significance of left ventricular diastolic dysfunction in essential hypertension. J Am Coll Cardiol 2002; 39: 2005-2011.
12. Braunwald E. Biomarkers in heart failure. N Engl J Med 2008; 358: 2148-2159.
13. Steen H, Giannitsis E, Futterer S et al. Cardiac troponin T at 96 hours after acute myocardial infarction correlates with infarct size and cardiac function. J Am Coll Cardiol 2006; 48: 2192-2194.
14. de Boer RA, Voors AA, Muntendam P et al. Galectin-3: a novel mediator of heart failure development and progression. Eur J Heart Fail 2009; 11: 811-817.
15. Nuver J, Smit AJ, van der Meer J et al. Acute chemotherapy-induced cardiovascular changes in patients with testicular cancer. J Clin Oncol 2005; 23: 9130-9137.
16. Cheitlin MD, Armstrong WF, Aurigemma GP et al. ACC/AHA/ASE 2003 guideline update for the clinical application of echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 2003; 16: 1091-1110.
17. Nagueh SF, Appleton CP, Gillebert TC et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009; 10: 165-193.
18. Christenson RH, Duh SH, Wu AH et al. Multi-center determination of galectin-3 assay performance characteristics: anatomy of a novel assay for use in heart failure. Clin Biochem 2010; 43: 683-690.
19. Kuczmarski RJ, Flegal KM, Campbell SM et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994; 272: 205-211.
20. Grundy SM, Cleeman JI, Daniels SR et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112: 2735-2752.
21. Nuver J, De Haas EC, Van Zweeden M et al. Vascular damage in testicular cancer patients: a study on endothelial activation by bleomycin and cisplatin in vitro. Oncol Rep 2010; 23: 247-253.
22. Yu M, Han J, Cui P et al. Cisplatin up-regulates ICAM-1 expression in endothelial cell via a NF-kappaB dependent pathway. Cancer Sci 2008; 99: 391-397.
23. Ishii H, Takada K. Bleomycin induces E-selectin expression in cultured umbilical vein endothelial cells by increasing its mRNA levels through activation of NFkappaB/Rel. Toxicol Appl Pharmacol 2002; 184: 88-97.
24. Shi Y, Inoue S, Shinozaki R et al. Release of cytokines from human umbilical vein endothelial cells treated with platinum compounds in vitro. Jpn J Cancer Res 1998; 89: 757-767.
25. Wang J, He D, Zhang Q et al. Resveratrol protects against cisplatin-induced cardiotoxicity by alleviating oxidative damage. Cancer Biother Radiopharm 2009; 24: 675-680.
26. Ma H, Jones KR, Guo R et al. Cisplatin compromises myocardial contractile function and mitochondrial ultrastructure: role of endoplasmic reticulum stress. Clin Exp Pharmacol Physiol 2009; 37: 460-465.
27. Nuver J, Smit AJ, Wolffenbuttel BH et al. The metabolic syndrome and disturbances in hormone levels in long-term survivors of disseminated testicular cancer. J Clin Oncol 2005; 23: 3718-3725.
28. Haugnes HS, Aass N, Fossa SD et al. Components of the metabolic syndrome in long-term survivors of testicular cancer. Ann Oncol 2007; 18: 241-248.
29. Hurrell DG, Nishimura RA, Ilstrup DM et al. Utility of preload alteration in assessment of left ventricular filling pressure by Doppler echocardiography: a simultaneous catheterization and Doppler echocardiographic study. J Am Coll Cardiol 1997; 30: 459-467.
30. Sohn DW, Chai IH, Lee DJ et al. Assessment of mitral annulus velocity by Doppler tissue imaging in the evaluation of left ventricular diastolic function. J Am Coll Cardiol 1997; 30: 474-480.
31. Galderisi M. Diastolic dysfunction and diastolic heart failure: diagnostic, prognostic and therapeutic aspects. Cardiovasc Ultrasound 2005; 3: 9.
32. De Sutter J, De Backer J, Van de Veire N et al. Effects of age, gender, and left ventricular mass on septal mitral annulus velocity (E') and the ratio of transmitral early peak velocity to E' (E/E'). Am J Cardiol 2005; 95: 1020-1023.
33. Wierzbowska-Drabik K, Krzeminska-Pakula M, Chrzanowski L et al. Agedependency of classic and new parameters of diastolic function. Echocardiography 2008; 25: 149-155.
34. Iurisci I, Tinari N, Natoli C et al. Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res 2000; 6: 1389-1393.